Adial Pharmaceuticals, Inc. (ADIL)

In the past six months, Adial Pharmaceuticals' stock has trended down. The company announced a reverse stock split and a public offering. Adial Pharmaceuticals regained compliance with Nasdaq's listing requirement. The company reported its 2025 fiscal year financial results and provided a business update. Adial Pharmaceuticals advanced its IP portfolio with a new U.S. utility patent application for AD04. The company submitted an application to the FDA Commissioner's National Priority Voucher Pilot Program for its AD04 clinical development program. Adial Pharmaceuticals successfully completed the manufacturing of a demonstration batch production for AD04. The company commended Congress on the introduction of bipartisan legislation aimed at expanding access to emerging AUD therapies for veterans. Adial Pharmaceuticals reported a net loss and stated that its existing cash is expected to fund operations into the second half of 2026, raising doubt about its ability to continue as a going concern.

Information regarding specific demand seasonality for Adial Pharmaceuticals, Inc.'s products and services is not available. As a clinical-stage biopharmaceutical company, its primary focus is on drug development and clinical trials rather than commercial sales, which typically exhibit seasonality. The demand for its lead product, AD04, once approved, would likely be driven by the prevalence of Alcohol Use Disorder and physician prescriptions, rather than seasonal fluctuations.

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for addiction and related disorders. Their lead product candidate is AD04, a genetically targeted serotonin-3 antagonist in Phase 3 clinical trials for Alcohol Use Disorder (AUD) in heavy drinking patients with specific genotypes. The company was founded in 2010 and is headquartered in Glen Allen, Virginia.

Adial Pharmaceuticals' market presence is focused on North America and Europe, with the aim of establishing AD04 as a leading pharmaceutical intervention in these regions. The company's corporate office is located in Glen Allen, Virginia, United States.

Adial Pharmaceuticals' reputation has been shaped by its progress in AD04 development and its financial situation. Positive events include advancements in its IP portfolio, successful manufacturing and regulatory progress, legislative support, and a peer-reviewed publication highlighting safety data. A significant event that could negatively impact its reputation is the disclosure of "going concern risk" due to limited funding.

Adial Pharmaceuticals, Inc. has a mixed ownership structure. Approximately 0.42% to <0.01% of the company's stock is owned by institutional investors, 30.91% by insiders, and 68.65% by public companies and individual investors. Major institutional owners include Armistice Capital, LLC, Citadel Advisors LLC, and Vanguard Group Inc. Major individual owners (insiders) include Cary J. Claiborne, William B. Stilley III, and Bankole A. Johnson.